{
    "ticker": "KROS",
    "name": "Keros Therapeutics, Inc.",
    "description": "Keros Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapeutics for patients with rare diseases and unmet medical needs. Founded in 2015, Keros is pioneering the advancement of therapies targeting the transforming growth factor-beta (TGF-\u03b2) superfamily of proteins, which play critical roles in various biological processes, including the regulation of muscle and bone health. The company's lead product candidate, KER-050, is designed to treat patients with myelodysplastic syndromes (MDS) and other hematologic disorders by enhancing erythropoiesis and improving red blood cell production. Keros is dedicated to addressing the needs of patients suffering from debilitating conditions by leveraging its proprietary drug discovery platform and expertise in TGF-\u03b2 biology. In addition to KER-050, the company is advancing additional programs aimed at addressing various muscle and bone disorders. Keros Therapeutics is committed to a patient-centric approach, ensuring that its research and development efforts are aligned with the needs of the communities it serves. The company's mission is to transform the lives of patients through innovative therapies while maintaining the highest standards of scientific integrity and ethics.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Lexington, Massachusetts, USA",
    "founded": "2015",
    "website": "https://www.kerostherapeutics.com",
    "ceo": "Dr. Jasper G. A. de Ruiter",
    "social_media": {
        "twitter": "https://twitter.com/KerosThera",
        "linkedin": "https://www.linkedin.com/company/keros-therapeutics/"
    },
    "investor_relations": "https://investors.kerostherapeutics.com",
    "key_executives": [
        {
            "name": "Dr. Jasper G. A. de Ruiter",
            "position": "CEO"
        },
        {
            "name": "Dr. Michael E. Kauffman",
            "position": "CMO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "KER-050",
                "KER-012"
            ]
        }
    ],
    "seo": {
        "meta_title": "Keros Therapeutics, Inc. | Innovative Therapies for Rare Diseases",
        "meta_description": "Explore Keros Therapeutics, Inc., a leader in biotechnology focused on developing innovative therapies for patients with rare diseases. Discover our mission and pipeline.",
        "keywords": [
            "Keros Therapeutics",
            "Biotechnology",
            "Rare Diseases",
            "Therapeutics",
            "KER-050",
            "Hematologic Disorders"
        ]
    },
    "faq": [
        {
            "question": "What does Keros Therapeutics focus on?",
            "answer": "Keros Therapeutics focuses on developing innovative therapeutics for patients with rare diseases and unmet medical needs."
        },
        {
            "question": "What is the lead product candidate of Keros?",
            "answer": "The lead product candidate of Keros is KER-050, aimed at treating myelodysplastic syndromes and other hematologic disorders."
        },
        {
            "question": "When was Keros Therapeutics founded?",
            "answer": "Keros Therapeutics was founded in 2015."
        },
        {
            "question": "Where is Keros Therapeutics headquartered?",
            "answer": "Keros Therapeutics is headquartered in Lexington, Massachusetts, USA."
        }
    ],
    "competitors": [
        "BMRN",
        "AMGN",
        "REGN"
    ],
    "related_stocks": [
        "VRTX",
        "ABBV",
        "GILD",
        "NVS"
    ]
}